IRADIMED CORP — Director's Dealing 2019

Dec 4, 2019

SEC Form 4/A — Form 4/A

Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2019-11-25

Reporting Person: JOHNSON BRENT (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-25	Common Stock	A	6000	$0.93	Acquired	7368	Direct
2019-11-25	Common Stock	S	6000	$22.8	Disposed	1368	Direct
2019-11-26	Common Stock	A	6000	$0.93	Acquired	7368	Direct
2019-11-26	Common Stock	S	6000	$22.65	Disposed	1368	Direct
2019-11-27	Common Stock	A	10000	$0.93	Acquired	11368	Direct
2019-11-27	Common Stock	S	10000	$21.96	Disposed	1368	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-25	Stock Option (Right to Buy)	$0.93	M	6000	Disposed	2022-11-01	Common Stock (6000)	Direct
2019-11-26	Stock Option (Right to Buy)	$0.93	M	6000	Disposed	2022-11-01	Common Stock (6000)	Direct
2019-11-27	Stock Option (Right to Buy)	$0.93	M	10000	Disposed	2022-11-01	Common Stock (10000)	Direct

Footnotes

F1: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.

F2: This transaction was executed in multiple trades at prices ranging from $22.75 to $22.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: This transaction was executed in multiple trades at prices ranging from $22.50 to $23.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: This transaction was executed in multiple trades at prices ranging from $21.75 to $22.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5: This option, representing a right to purchase a total of 278,408 shares, was granted on November 1, 2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date.